In cirrhosis, myostatin levels are decreased in patients with acute decompensation and acute-on-chronic liver failure (ACLF), and low serum myostatin independently predicts ACLF development and mortality, irrespective of liver disease severity or sex. This evidence concerns the gene MSTN and acute-on-chronic liver failure.